A new systematic review and meta-analysis published in the Clinical Nutrition ESPEN revealed promising outcomes for the ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.